Biosplice
biosplice.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Biosplice About Board of Directors Management Advisors Contact Us Publications Our Programs Osteoarthritis Other Programs News Careers Over 50 million US patients suffer from osteoarthritis, with no drugs available to arrest the disease.
News
UK's MHRA Accepts Biosplice's Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Assessment
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (
Read more
Report
Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis
LOR is the first drug candidate with disease-modifying potential for osteoarthritis submitted for approval, demonstrating statistically and clinically significant improvements in pain, function and medial joint space width when compared with placebo, alon
Read more
Report
Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis
LOR is the first drug candidate with disease-modifying potential for osteoarthritis submitted for approval, demonstrating statistically and clinically significant improvements in pain, function and medial joint space width when compared with placebo, alon
Read more
Report
Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis
Read more
Report
Biosplice Therapeutics Announces First Patient Dosed in Investigator-Initiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD Platinum-Resistant Ovarian Cancer
Study at the University of Colorado Anschutz Cancer Center builds on preclinical data showing that cirtuvivint plus PARP inhibition overcame resistance in preclinical models of high-grade serous ovarian cancer
Read more
Report
Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas
Multicenter study sponsored by SELNET to evaluate cirtuvivint as a second-line monotherapy in selected sarcoma subtypesSAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (
Read more
Report
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program
The competitive Department of Defense
Read more
Report
Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis
Read more
Report
Biosplice announces Interim data from phase 3 long-term extension trial in knee osteoarthritis and initiates new phase 3 trial
Biosplice announces Interim data from phase 3 long-term extension trial in knee osteoarthritis and initiates new phase 3 trial
Read more
Report
Show more news